uniQure N.V. (QURE)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of uniQure N.V. (“uniQure” or “the Company”) (NASDAQ: QURE). Investors who purchased uniQure securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether uniQure has violated federal securities laws.
Investigation Details
On November 3, 2025, uniQure issued a press release issued announcing that it “believes that the FDA currently no longer agrees that data from the Phase I/II studies of AMT-130 in comparison to an external control, as per the prespecified protocols and statistical analysis plans shared with the FDA in advance of the analyses, may be adequate to provide the primary evidence in support of a BLA submission.” The Company added, “Consequently, the timing of the BLA submission for AMT-130 is now unclear.” Following this news, uniQure stock dropped by more than 57% in morning trading on the same day.
What’s Next?
If you are aware of any facts relating to this investigation or purchased uniQure securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | [email protected]